Sugi Predict

Sugi Predict / Compounds / SCHEMBL241706

SCHEMBL241706

SCHEMBL241706

Oc1cc2ccccc2nn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.50
▸ KDM4E B2RXH2 4/20 0.50
▸ HPGD P15428 3/20 0.50
▸ GLA P06280 3/20 0.50
▸ MAPT P10636 3/20 0.50
▸ ACHE P22303 1/20 0.50
▸ GAA P10253 3/20 0.47
▸ STAT3 P40763 1/20 0.47
▸ NQO2 P16083 2/20 0.42
▸ GPR3 P46089 1/20 0.40
▸ CYP1A2 P05177 2/20 0.39
▸ MGAM O43451 1/20 0.38
▸ PDPK1 O15530 1/20 0.38
▸ TRPM4 Q8TD43 1/20 0.38
▸ HTR3A P46098 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ IKBKB O14920 1/20 0.37
▸ RAB9A P51151 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14861002 0.82 NQO2 (0.44) ALDH1A1KDM4EHPGDGLAMAPT
SCHEMBL31115164 0.75 ALDH1A1 (0.55) ALDH1A1KDM4EHPGDGLAMAPT
SCHEMBL5483645 0.75 ALDH1A1 (0.55) ALDH1A1KDM4EHPGDGLAMAPT
SCHEMBL3244658 0.74 KDM4E (0.44) ALDH1A1KDM4EHPGDGLAMAPT
SCHEMBL30248459 0.73 ALDH1A1 (0.52) ALDH1A1KDM4EHPGDGLAMAPT
SCHEMBL11173734 0.73 ALDH1A1 (0.52) ALDH1A1KDM4EHPGDGLAMAPT
SCHEMBL5245198 0.71 KDM4E (0.55) ALDH1A1KDM4EHPGDGLAMAPT
SCHEMBL2781561 0.71 KDM4E (0.50) ALDH1A1KDM4EHPGDGLAMAPT
SCHEMBL329496 0.71 KDM4E (0.50) ALDH1A1KDM4EHPGDGLAMAPT
Hydrochloric Acid SCHEMBL21979894 0.71 ALDH1A1 (0.50) ALDH1A1KDM4EHPGDGLAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0387119-B1 Process for the condensation of at least one epoxide with at least one cyclic anhydride in the presence of a catalyst based on at least one nitrogen containing titanium complex INST FRANCAIS DU PETROLE (FR) 1993-11-18 — — EP claimed
US-5030711-A Process for condensing at least one epoxide on at least one cyclic anhydride in the presence of a catalyst consisting of at least one titanium nitrogenous complex INSTITUT FRANCAIS DU PETROLE (FR) 1991-07-09 — — US claimed
US-4997910-A Polyesters INSTITUT FRANCAIS DU PETROLE (FR) 1991-03-05 — — US claimed
US-20250289830-A1 KRAS INHIBITORS ELI LILLY AND COMPANY 2025-09-18 — — US disclosed
US-12351591-B2 KRas inhibitors ELI LILLY AND COMPANY (US) 2025-07-08 — — US disclosed
EP-4499233-A1 KRAS INHIBITORS Eli Lilly and Company (US) 2025-02-05 — — EP disclosed
CN-119095853-A KRAS inhibitors 伊莱利利公司 2024-12-06 — — CN disclosed
CN-114746414-B Aza-quinoline compounds and uses thereof 诺华公司 2024-10-18 — — CN disclosed
US-20240043451-A1 KRAS INHIBITORS ELI LILLY AND COMPANY 2024-02-08 — — US disclosed
WO-2023183585-A1 KRAS INHIBITORS ELI LILLY AND COMPANY (US) 2023-09-28 — — WO disclosed
WO-2023094615-A1 SYNTHETIC EICOSANOID ANALOGUES FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH INCREASED GDF15 PLASMA CONCENTRATION OMEICOS THERAPEUTICS GMBH (DE) 2023-06-01 — — WO disclosed
US-5030711-A Process for condensing at least one epoxide on at least one cyclic anhydride in the presence of a catalyst consisting of at least one titanium nitrogenous complex INSTITUT FRANCAIS DU PETROLE (FR) 1991-07-09 — — US disclosed
US-5006537-A Analgesics, memory enhancement, Alzheimer* disease HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) 1991-04-09 — — US disclosed
EP-0415102-A1 1,3-Dihydro-1-(pyridinylamino)-2H-indol-2-ones, a process for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1991-03-06 — — EP disclosed
EP-0415103-A1 2,3-Dihydro-1-(pyridinylamino)-indoles, a process for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1991-03-06 — — EP disclosed
US-4997910-A Polyesters INSTITUT FRANCAIS DU PETROLE (FR) 1991-03-05 — — US disclosed
EP-0380264-A2 Halogenation process DowElanco (US) 1990-08-01 — — EP disclosed
EP-0317188-A2 Heteroaromatic enamide derivatives and their use as pesticides ROUSSEL UCLAF (FR) 1989-05-24 — — EP disclosed
US-4600681-A Color photographic material with azo dicyanoimidazole dyes AGFA-GEVAERT AKTIENGESELLSCHAFT (DE) 1986-07-15 — — US disclosed
US-4038240-A PROCESS FOR DYEING POLYURETHANE RESINS BAYER AKTIENGESELLSCHAFT (DT) 1977-07-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240043451-A1 KRAS INHIBITORS KRAS, NRAS, HRAS ALDH1A1 1852/4885KDM4E 2640/4885HPGD 2297/4885
US-12351591-B2 KRas inhibitors KRAS, NRAS, HRAS ALDH1A1 1852/4885KDM4E 2640/4885HPGD 2297/4885
US-20250289830-A1 KRAS INHIBITORS KRAS, NRAS, HRAS ALDH1A1 1852/4885KDM4E 2640/4885HPGD 2297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.